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A B S T R A C T
The aim of this investigation was to determine the seroprevalence of H. pylori in patients with coronary artery disease
(CAD). Patients with coronary artery disease (n=90) and control group (n=90) were enrolled into this randomized,
multi-centre study. CAD risk factors analyzed included age, male gender, diabetes mellitus, systemic hypertension, ciga-
rette smoking, hypercholesterolemia and socioeconomic status. The results of this study showed a higher seroprevalence
of Helicobacter pylori infection in patients with CAD compared to controls (78,8% versus 58,3%, p<0.05). However, Heli-
cobacter pylori seropositivity was not associated with coronary artery risk factors (smoking, body mass index, diabetes
mellitus, hypertension, total cholesterol and socioeconomic status) either in the whole study population or in the patients
and control subjects analyzed separately (P>0.05). Further study are needed to clarify the precise role of Helicobacter
pylori infection on the development of coronary artery disease.
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Introduction
Helicobacter pylori, a gram-negative, microaerophilic
spiral bacterium, has been found to infect the gastric mu-
cosa of over half the world s population1. Helicobacter
pylori gastritis is associated with the development of pep-
tic ulcer, gastric adenocarcinoma and gastric MALT lym-
phoma2. Helicobacter pylori infection may induce a chro-
nic systemic inflammatory status of low degree, which
may have repercussions for the whole organism. Sys-
temic indices of inflammation, such as levels of poly-
morphs and monocytes, are increased in H. pylori-in-
fected dyspeptic patients, and many vasoactive substances
and cellular mediators, such as cytokines, which are pro-
duced in the gastric mucosa in response to H. pylori in-
fection, may be transported in the blood-stream and pro-
mote an inflammatory response in organs distant from
the stomach3,4.
Several preliminary reports have suggested that chro-
nic infections by H. pylori, as well as other chronic infec-
tions, may be associated with atherosclerosis and vascu-
lar diseases5,6. However, most prospective studies have
not confirmed the association between chronic infections
and coronary disease7–10. Furthermore, H. pylori infec-
tion is associated with several confounding factors, par-
ticularly low social class, which are also related to higher
incidence of vascular diseases5.
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The aim of this investigation was to determine the
seroprevalence of H. pylori in patients with coronary ar-
tery disease.
Materials and Methods
Patients with coronary artery disease (n=90) and
control group (n=90) were enrolled into this random-
ized, multi-centre study.
All subjects had given informed consent to inclusion
in the study and the research was carried out in accor-
dance with the principles of the Declaration of Helsinki.
The diagnosis of coronary artery disease (CAD) re-
quired the presence of one of following: a history of coro-
nary artery bypass graft surgery, a history of myocardial
infarction or a history of percutaneous transluminal cor-
onary stent. Exclusion criteria were: prior H. pylori erad-
ication therapy, consumption of acid-suppressive drugs
or antibiotics in the preceding 12 months, history of
vagotomy or operations on the upper gastrointestinal
tract and a known history of gastrointestinal pathology.
CAD risk factors analyzed included age, male gender,
diabetes mellitus, systemic hypertension, cigarette smok-
ing, hypercholesterolemia and socioeconomic status. We
used occupational status as the socioeconomic status in-
dicator. Patients were considered to have systemic hyper-
tension if they had received the diagnosis with an arte-
rial pressure>140/90 mm Hg or were being treated with
antihypertensive medications or dietary modification. A
history of past and current smoking of each patient was
obtained. Patients who had stopped smoking >20 years
ago and who were <30 years of age when they stopped
were considered not to have smoking as a risk factor. Pa-
tients were considered to have diabetes mellitus if they
had a fasting plasma glucose >6.4 mmol/L, were taking
insulin or oral hypoglycemic agents or had previously re-
ceived such treatment, or were currently using dietary
modification to control the condition. Patients were con-
sidered to have hyperlipidemia if they had a serum cho-
lesterol value >5.2 mmol/L or were receiving cholesterol-
lowering treatment.
Potential control subjects were excluded if they exhib-
ited one or more of the following: a known history of
CAD, a known history of gastrointestinal pathology, chest
pain and dyspnea, prior Helicobacter pylori eradication
therapy, consumption of acid-suppressive drugs or anti-
biotics in the preceding 12 months, a history of vagotomy
or operations on the upper gastrointestinal tract or a
known history of gastrointestinal pathology. We selected
90 controls from among the healthy subjects and match-
ed them with the patients for sex, age and coronary ar-
tery risk factors.
All subjects enrolled (CAD patients and controls) un-
derwent an enzyme-linked Immulite (chemiluminescent)
analyzer IgG serologic test for H. pylori diagnosis (Diag-
nostic Products Corp., Los Angeles, CA, USA), in accor-
dance with the manufacturer s guidelines. This kit has a
sensitivity of 97% and a specificity of 98.%.
Results are presented as mean ±SD (standard devia-
tion). Statistical analysis was carried out using SPSS
software (Statistical Package for the Social Sciences, ver-
sion 11.0, SPSS Inc., Chicago, IL,USA) and chi-square
and Student t-tests. A value of P<0.05 was considered
statistically significant.
Results
In Table 1. are listed demographic data on the pati-
ents and controls. There was no significant difference in
age, sex or coronary artery risk factors between the two
groups, but the prevalence of seropositivity for Helico-
bacter pylori was higher in patients compared to controls
(78,8% versus 58,3%, P<0.05). However, Helicobacter
pylori seropositivity was not associated with coronary ar-
tery risk factors (smoking, body mass index, diabetes
mellitus, hypertension, total cholesterol and socioeco-
nomic status) either in the whole study population or in
the patients and control subjects analyzed separately
(P>0.05) as reported in Tables 2 and 3.
Discussion
Since 1994, a considerable number of studies have
been performed on the correlation between Helicobacter
pylori infection and ischaemic heart disease. The exact
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TABLE 1
DEMOGRAPHIC DATA OF PATIENTS AND CONTROL GROUP
Patients (n=90) Controls (n=90) value*
Age (mean years) 49.2 50.8 NS
Male (%) 67.5 68.7 NS
Hypertension (%) 59.6 55.8 NS
widctlparSmoking (%) 67.2 62.9 NS
Diabetes mellitus (%) 19.7 15.2 NS
Body mass index (kg/m2) 29.5 26.2 NS
Total cholesterol (mmol/L) 6.9 5.1 NS
Socioeconomic status (high, %) 45.7 49.1 NS
Seropositivity to Helicobacter pylori IgG antibody (%) 78.8 55.5 P<0.05
*NS, P>0.05
pathogenetic role of H. pylori infection in atherosclerosis
is still a matter of debate, and the process that underlies
this association is also unclear.
Epidemiological and molecular studies as well as some
eradicating trials gave conflicting results.
Mendall et al.5 in 1994 reported a higher prevalence of
H. pylori infections in patients with ischaemic heart dis-
ease (IHD). This finding has since been verified by sev-
eral other authors. Danesh et al.11 showed evidence of
strong association between IHD and serological markers
of persistent infection sustained by H. pylori. These re-
sults were confirmed by other studies in which higher
levels of anti H. pylori antibodies were found in patients
with IHD or who had died of myocardial infarction (MI)
than in normal controls12,13. Pasceri et al.14 have demon-
strated a higher prevalence of either H. pylori infection
or CagA-positive strains in patients with IHD than in
controls. Singh et al.15 in a similar study, found a preva-
lence of H. pylori CagA-positive strains in 52% of the
IHD patients compared to 43% of the controls. The asso-
ciation remained significant even after the adjustment
for blood pressure values, body mass indeks, plasma con-
centrations of low-density lipoprotein and high-density
lipoprotein cholesterol, history of hypertension and dia-
betes, statin treatment and socioeconomic status. Ko-
walski et al.16 reported a higher prevalence of H. pylori
infection in patients with unstable angina or MI as well
as an evidence of H. pylori-related DNA in atheroscle-
rotic lesions of 47,8% patients with coronary heart dis-
ease.
Some epidemiological study did not show any clear
correlation between H. pylori infection and IHD17,18. No
significant association was found concering H. pylori in-
fection among patients with angiographically document-
ed coronary artery disease19–21, and in patients with high
risk of restenosis after coronary intervention22. In Ko-
enig et al.23 and Whincup et al.24 studies none of the in-
flammatory markers (CRP, fibrinogen, plasma viscosity
or leucocyte counts) was significantly different in pa-
tients with H. pylori infection and in controls, thus deny-
ing any positive correlation between those events.
Kowalski et al.25 proved that H. pylori eradication sig-
nificantly attenuates the reduction in coronary artery lu-
men in patients with coronary artery disease after per-
cutaneous coronary angioplasty, possibly by reducing the
effect of proinflammatory cytokines. Another study26 has
evaluated the effect of the eradication of H. pylori infec-
tion on the plasma levels of total cholesterol, LDL choles-
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TABLE 2







Age (years) 50.1+9 48.6+6 NS
Men (%) 67.9 66.7 NS
Smoker (%) 67.5 66.1 NS
Diabetes mellitus 20.1 19.1 NS
Total cholesterol > 5,2mmol/L (%) 59.6 55.7 NS
Socioeconomic status (high,%) 43.9 47.8 NS
Data are presented as mean+SD or percentage of patients.
*NS, P>0.05
TABLE 3







Age (years) 50.1+7 49.6+9 NS
Men (%) 69.5 67.9 NS
Smoker (%) 63.4 62.6 NS
Diabetes mellitus 20.3 19.1 NS
Total cholesterol > 5,2 mmol/L (%) 50.6 48.7 NS
Socioeconomic status (high, %) 48.9 49.8 NS
Data are presented as mean+SD or percentage of patients.
*NS, P>0.05
terol, fibrinogen and IL-8. In particular, all those factors
were significantly decreased after the administration of
the eradicating treatment.
Other studies did not confirm any beneficial effect of
the eradicating treatment on the known risk for ischa-
emic heart disease. Schweeger et al.27 demonstrated that
successful eradication of H. pylori do not determine any
change in either fibrinogen or other proteins of the acute
phase levels. Stone et al.28 did not find any correlation
between eradication of H. pylori infection and risk fac-
tors for ischaemic heart disease.
In conclusion, the results of this study showed a
higher seroprevalence of Helicobacter pylori infection in
patients with CAD compared to controls (78,8% versus
58,3%, p<0.05). However, Helicobacter pylori seropo-
sitivity was not associated with coronary artery risk fac-
tors (smoking, body mass index, diabetes mellitus, hyper-
tension, total cholesterol and socioeconomic status) either
in the whole study population or in the patients and con-
trol subjects analyzed separately (P>0.05). Further study
are needed to clarify the precise role of Helicobacter
pylori infection on the development of coronary artery
disease
R E F E R E N C E S
1. POUNDER RE, Aliment Pharmacol Ther, 9 Suppl (1996) 33. — 2.
MARSHALL BJ, Am J Gastroenterol, 89 Suppl (1994 S116. — 3. GRA-
HAM DY, OSATO MS, OLSON CA, ZHANG J, FIGURA N, Helicobacter,
3 (1998) 174. — 4. PERRI F, R.. CLEMANTE R, FESTA V, CHECCHIA
DE AMBROSIO C, QUITADAMO M, FUSILLO M, GROSSI E, ANDRI-
ULI A, Ital J Gastroenterol Hepatol, 31 (1999) 290. — 5. MENDALL MA,
GOGGIN PM, MOLINEAUX N, Br Heart J, 71 (1994) 437. — 6. DA-
NESH J, COLLINS R, PETO R, Lancet, 350 (1997) 430. — 7. WHINCUP
P, MENDALL MA, PERRY IJ, Heart, 75 (1996) 568. — 8. WALD NJ, LAW
MR, MORRIS JK, BMJ, 315 (1997) 1199. — 9. FOLSOM AM, NIETO JF,
SORLIE P, Circulation, 98 (1998) 845. — 10. HAIDER AW, WILSON
PWF, LARSON MG, J Am Coll Cardiol, 40 (2002) 1408. — 11. DANESH J,
WONG Y, WARD M, MUIR J, Heart, 81 (1999) 245. — 12. ALKOUT AM,
RAMSAY EJ, MACKENZIE DA, FEMS Immunol Med Microbiol, 29
(2002) 271. — 13. PELLICANO R, MAZZARELLO MG, MORELLONI S,
Int J Clin Lab Res, 29 (1999) 141. — 14. PASCERI V, CAMMAROTA G,
PATTI G, Circulation, 97 (1998) 1675. — 15. SINGH RK, MCMAHON
AD, PATEL H, Heart, 88 (2002) 43. — 16.KOWALSKI M, REES W,
KONTUREK PC, Dig Liver Dis, 34 (2002) 398. — 17. ZITO F, DI CA-
STELNUOVO A, D ORAZIO A, Thromb Haemost, 82 (1999) 14. — 18.
HOFFMEISTER A, ROTHENBACHER D, BODE G, Arterioscler Thromb
Vasc Biol, 21 (2001) 427. — 19. TASI CJ, HUANG TY, Dig Dis Sci, 45
(2000) 1227. — 20. STOLLBERGER C, MOLZER G, FINSTERER J, Clin
Diagn Lab Immunol, 8 (2001) 997. — 21. CARLSSON J, MIKETI] S,
BROM J, ROSS R, BACHMANN H, TEBBE U, Int J Cardiol, 73 (2000)
165. — 22. SCHIELE F, BATUR MK, SERONDE MF, MENEVEAU N,
SEWOKE P, BASSIGNOT A, Heart, 85 (2001) 304. — 23. KOENIG W,
ROTHENBACHER D, HOFFMEISTER A, MILLER M, BODE G, AD-
LER G, Circulation, 100 (1999) 2326. — 24. WHINCUP P, DANESH J,
WALKER M, LENNON L, THOMSON A, APPLEBY P, Circulation, 101
(2000) 1647. — 25. KOWALSKI M, KONTUREK PC, PIENIAZEK P,
KARCZEWSKA E, KLUCZKA A, GROVE R, Dig Liver Dis, 33 (2001) 222.
— 26. MAJKA J, ROG T, KONTUREK PC, BIELANSKI W, KOWALSKI
M, Med Sci Monit, 8 (2002) CR675. — 27. SCHWEEGER I, FITSCHA P,
SINZINGER H, Tromb Res, 97 (2000) 411. — 28. STONE AF, MENDALL
MA, KASKI JC, EDGER TM, RISLEY P, POLONIECKI J, Circulation,
106 (2002) 1219.
A. V~ev
Department of Internal Medicine, School of Medicine, University »J.J. Strossmayer» Osijek, J. Huttlera 4,
31000 Osijek, Croatia
e-mail: vcev.aleksandarºkbo.hr
HELICOBACTER PYLORI INFEKCIJA I KORONARNA ARTERIJSKA BOLEST
S A @ E T A K
Cilj ovog rada je bio odrediti seroprevalenciju Helicobacter pylori infekcije u bolesnika s koronarnom arterijskom
bole{}u. U ovu randomiziranu multicentri~nu studiju uklju~eno je 90 bolesnika s koronarnom arterijskom bole{}u i 90
zdravih osoba u kontrolnoj skupini. Analizirani su rizi~ni ~imbenici za koronarnu arterijsku bolest i to: dob, spol, pu-
{enje, prekomjerna tjelesna te`ina, arterijska hipertenzija, ukupni kolesterol u krvi, {e}erna bolest i socioekonomski
status ispitanika. Rezultati su pokazali statisti~ki zna~ajnu ve}u seroprevalenciju H. pylori infekcije u bolesnika s koro-
narnom arterijskom bole{}u nego u ispitanika kontrolne skupine (79,1% nasuprot 58,3%, P<0,05). Me|utim, H. pylori
seropozitivnost nije bila udru`ena s ~imbenicima rizika za koronarnu arterijsku bolest gledaju}i ukupan broj ispitanika
(n=180) ili gledaju}i posebno bolesnike, a posebno ispitanike u kontrolnoj skupini (P>0,05). Potrebne su budu}e stu-
dije kako bi se precizno odredila uloga H. pylori infekcije u nastanku koronarne arterijske bolesti
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